Live Breaking News & Updates on Eric poma

Stay informed with the latest breaking news from Eric poma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Eric poma and stay connected to the pulse of your community

Molecular Templates (MTEM) Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at AACR

Molecular Templates (MTEM) Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at AACR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , San-diego , California , American , Eric-poma , Molecular-templates-inc , Nasdaq , American-association-for-cancer-research-annual-meeting , Molecular-templates , Interim-data , Cancer-research-annual-meeting , Interim-data-location

Molecular Templates Presents Interim Data from MT-6402

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

United-states , Texas , San-diego , California , American , Eric-poma , Molecular-templates-inc , Exchange-commission , Nasdaq , American-association-for-cancer-research-annual-meeting , Interim-data , Cancer-research-annual-meeting

What's Going On With Molecular Templates Stock? - Molecular Templates (NASDAQ:MTEM)

Molecular Templates shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. Molecular Templates said the findings show that MT-6402 acts uniquely from other approved checkpoint agents and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed. "We are excited to see objective responses in heavily pre-treated, checkpoint-experienced, head and neck cancer patients, a setting with high unmet medical need," said CEO Eric Poma.

Eric-poma , Lufax-holding , Benzinga-pro , Going-on-with-sofi-technologies , Molecular-templates ,

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable s

Texas , United-states , San-diego , California , American , Bristol-myers-squibb , Eric-poma , American-association-for-cancer-research , Nasdaq , Molecular-templates-inc , Chief-executive , Chief-scientific-officer

Molecular Templates, Inc. Reports Third Quarter 2023

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

Miami , Florida , United-states , New-york , Texas , Eric-poma , Maurizio-voi , Bristol-myers-squibb , Stifel-annual-health-care-conference , Nasdaq , Lotte-new-york-palace-hotel , Kimpton-epic-hotel

Molecular Templates Announces First Patient Dosed in Phase

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

Texas , United-states , Eric-poma , Nasdaq , Exchange-commission , Molecular-templates-inc , Antigen-seeding-technology , Microsatellite-instability-high , Mismatch-repair-deficient , Chief-executive , Chief-scientific-officer , Shiga-like-toxin

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Texas , United-states , Eric-poma , Molecular-templates-inc , Nasdaq , Exchange-commission , Antigen-seeding-technology , Templates-announces-first-patient-dosed , Novel-engineered-toxin-body-targeting , Advanced-solid , Microsatellite-instability-high , Mismatch-repair-deficient

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Italy , Texas , United-states , Maurizio-voi , Eli-lilly , Eric-poma , Global-clinical-program-head , Nasdaq , Molecular-templates-inc , Exchange-commission , University-of-padua , Novartis

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

AUSTIN, Texas, Sept. 28, 2023 -- Molecular Templates, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action,...

Texas , United-states , Italy , Eli-lilly , Maurizio-voi , Eric-poma , University-of-padua , Nasdaq , Exchange-commission , Global-program-head , Molecular-templates-inc , School-of-medicine

Molecular Templates Announces the Appointment of Dr.

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...

Texas , United-states , Italy , Eric-poma , Maurizio-voi , Eli-lilly , Bristol-myers-squibb , Novartis , Research-development , Pfizer , Global-clinical-program-head , Global-program-head